¼¼°èÀÇ ºê·£µå Á¦³×¸¯ ½ÃÀå
Branded Generics
»óǰÄÚµå : 1777887
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 354 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,195,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,585,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ºê·£µå Á¦³×¸¯ ½ÃÀåÀº 2030³â±îÁö 3,285¾ï ´Þ·¯¿¡ µµ´Þ

2024³â¿¡ 2,563¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ºê·£µå Á¦³×¸¯ ¼¼°è ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGR 4.2%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 3,285¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ °­¾ÐÁ¦´Â CAGR 4.2%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 675¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¾ËųȭÁ¦ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 3.9%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 698¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 7.7%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹Ãø

¹Ì±¹ÀÇ ºê·£µå Á¦³×¸¯ ½ÃÀåÀº 2024³â¿¡ 698¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 670¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 7.7%·Î ÃßÁ¤µË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 1.8%¿Í 3.3%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.5%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ ºê·£µå Á¦³×¸¯ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

ºê·£µå Á¦³×¸¯ÀÌ ½ÃÀåÀ» ÁÖµµÇÏ´Â ÀÌÀ¯´Â ¹«¾ùÀϱî?

ºê·£µå Á¦³×¸¯Àº ǰÁú°ú È¿´ÉÀ» À¯ÁöÇϸ鼭 ºê·£µå 󹿾àÀ» ´ëüÇÒ ¼ö ÀÖ´Â ºñ¿ë È¿À²ÀûÀÎ ´ë¾ÈÀ» Á¦°øÇϱ⠶§¹®¿¡ Á¡Á¡ ´õ ¸¹Àº Àα⸦ ¾ò°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀǾàǰÀº ÀçÆ÷ÀåµÇ¾î ºê·£µå À̸§À¸·Î ÆÇ¸ÅµÇ¸ç, Á¾Á¾ ¿ø·¡ÀÇ Á¦Á¶¾÷ü³ª ´Ù¸¥ Á¦¾àȸ»ç¿¡¼­ Á¦Á¶ÇÏ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ºê·£µå ÀǾàǰÀÇ ºñ¿ëÀÌ »ó½ÂÇϰí Àú·ÅÇÑ ÀÇ·á ¼­ºñ½ºÀÇ Çʿ伺ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ºê·£µå Á¦³×¸¯Àº ÀǾàǰ ½ÃÀåÀÇ Áß¿äÇÑ °ÝÂ÷¸¦ ¸Þ¿ì°í ÀÖ½À´Ï´Ù. ÀÇ·áÁø°ú ȯÀÚ ¸ðµÎ ½Å·Úµµ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ºñ¿ëÀû ÀÌÁ¡ µîÀ» ÀÌÀ¯·Î ºê·£µå Á¦³×¸¯À» ¼±ÅÃÇϰí ÀÖ½À´Ï´Ù. ¼¼°è °¢±¹ Á¤ºÎ°¡ ÀÇ·áºñ Àý°¨À» À§ÇØ Á¦³×¸¯ ÀǾàǰ µµÀÔÀ» ÃßÁøÇÏ´Â °¡¿îµ¥, ºê·£µå Á¦³×¸¯¿¡ ´ëÇÑ ¼ö¿ä´Â ²ÙÁØÈ÷ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

±ÔÁ¦¿Í ½ÃÀå Àü·«Àº ¾î¶»°Ô »ê¾÷À» Çü¼ºÇϰí Àִ°¡?

½ÃÀå »óȲÀº ºê·£µå Á¦³×¸¯ ½ÃÀåÀÇ ¼ºÀå¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¸¹Àº ±¹°¡¿¡¼­ Á¦³×¸¯ ÀǾàǰÀÇ Ã¤ÅÃÀ» ÃËÁøÇϱâ À§ÇØ ÀǾàǰ ½ÂÀÎ ÀýÂ÷¸¦ °£¼ÒÈ­ÇÏ¿© Á¦¾à»ç°¡ ºê·£µå Á¦³×¸¯À» ½±°Ô µµÀÔÇÒ ¼ö ÀÖµµ·Ï Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ºí·Ï¹ö½ºÅÍ ÀǾàǰÀÇ Æ¯Çã ¸¸·á´Â Á¦¾à»çµé¿¡°Ô Á¦³×¸¯ ÀǾàǰÀÇ ¸®ºê·£µù ±âȸ¸¦ Á¦°øÇÏ¿© »õ·Î¿î ¼öÀÍ¿øÀ» Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, ÀÇ»çÀÇ Ãßõ, Àû±ØÀûÀÎ °¡°Ý Àü·«, ¼ÒºñÀÚ ÀÎ½Ä °³¼± Ä·ÆäÀÎ µîÀÇ Àü·«Àû ¸¶ÄÉÆÃÀÌ Á¦¾à»çÀÇ ºê·£µå Á¦³×¸¯ Æ÷Æ®Æú¸®¿À È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ½ÃÀå °æÀïÀÌ Ä¡¿­ÇØÁü¿¡ µû¶ó °¢ »çµéÀº Çõ½ÅÀûÀÎ Á¦Á¦ ¹× ¹ÙÀÌ¿À½Ã¹Ð·¯¿¡ ÅõÀÚÇÏ¿© Á¦Ç° Â÷º°È­¿Í °æÀï·Â °­È­¸¦ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù.

ºê·£µå Á¦³×¸¯ÀÇ Ã¤ÅÃÀ» ÃËÁøÇÏ´Â Ä¡·á ºÐ¾ß´Â ¹«¾ùÀΰ¡?

ºê·£µå Á¦³×¸¯Àº ½ÉÇ÷°ü Áúȯ, Á¾¾çÇÐ, ½Å°æÇÐ, ´ç´¢º´ °ü¸® µî ¿©·¯ Ä¡·á ºÐ¾ß¿¡ Å©°Ô ÁøÃâÇϰí ÀÖ½À´Ï´Ù. ºñ¿ë È¿À²ÀûÀÎ ¸¸¼º Áúȯ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä´Â ½ÃÀå È®´ëÀÇ ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ½ÅÈï °æÁ¦±¹¿¡¼­´Â ÀÇ·á ÀÎÇÁ¶ó°¡ ¾ÆÁ÷ °³¹ß ÁßÀ̱⠶§¹®¿¡ ºê·£µå Á¦³×¸¯Àº Àå±âÀûÀÎ Áúº´ °ü¸®¸¦ À§ÇÑ Àú·ÅÇÑ ´ë¾ÈÀ» Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, ºê·£µå Á¦³×¸¯ Áß ±Þ¼ºÀåÇϰí ÀÖ´Â ¹ÙÀÌ¿À½Ã¹Ð·¯ ÀǾàǰÀº ÀÚ°¡¸é¿ªÁúȯ ¹× ¾Ï Ä¡·á¿¡ Çõ¸íÀ» ÀÏÀ¸Å°¸ç °í°¡ÀÇ »ý¹°ÇÐÀû Á¦Á¦¿¡ ´ëÇÑ ÀÇÁ¸µµ¸¦ ³·Ãß°í ÀÖ½À´Ï´Ù. »ýȰ½À°üº´¿¡ ´ëÇÑ ºÎ´ã Áõ°¡¿Í Á¢±Ù¼º ³ôÀº Ä¡·á ¿É¼ÇÀÇ Çʿ伺ÀÌ ´Ù¾çÇÑ ÀÇ·á ºÐ¾ß¿¡¼­ ºê·£µå Á¦³×¸¯ÀÇ µµÀÔÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

ºê·£µå Á¦³×¸¯ ½ÃÀåÀÇ ¼ºÀåÀº ÀÇ·áºñ »ó½Â, ƯÇã ¸¸·á Áõ°¡, ÀǾàǰ À¯Åë¸Á È®´ë µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. Á¤ºÎ¿Í º¸Çè»ç´Â ¾àÁ¦ºñ Àý°¨°ú ÀǾàǰ Á¢±Ù¼º Çâ»óÀ» À§ÇØ ºê·£µå Á¦³×¸¯ÀÇ »ç¿ëÀ» Àû±Ø Àå·ÁÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¦¾à»çµéÀº µðÁöÅÐ Ç÷§Æû°ú ÀüÀÚ»ó°Å·¡ ä³ÎÀ» Ȱ¿ëÇÏ¿© Á¦Ç° °¡¿ë¼º ¹× ¼ÒºñÀÚ Á¢±Ù¼ºÀ» °­È­Çϰí ÀÖ½À´Ï´Ù. °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿Í Ç¥Àû Ä¡·áÀÇ ºÎ»óµµ È¿´É°ú ¾ÈÀü¼ºÀ» °³¼±ÇÑ Ã·´Ü ºê·£µå Á¦³×¸¯ °³¹ß¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. Á¦¾à »ê¾÷ÀÌ °è¼Ó ÁøÈ­ÇÏ´Â °¡¿îµ¥, ºê·£µå Á¦³×¸¯Àº ºñ¿ë È¿À²¼º°ú °íǰÁú ÇコÄÉ¾î ¼Ö·ç¼ÇÀÇ ±ÕÇüÀ» ¸ÂÃß´Â µ¥ ÇʼöÀûÀÎ ¿ªÇÒÀ» ÇÒ °ÍÀ¸·Î ±â´ëµÇ°í ÀÖ½À´Ï´Ù.

ºÎ¹®

¾àÁ¦ Ŭ·¡½ºº°(°­¾ÐÁ¦, ¾ËųȭÁ¦, È£¸£¸óÁ¦, ÁöÁú ÀúÇÏÁ¦, Ç׿ì¿ïÁ¦, Ç×Á¤½Åº´Á¦, Ç×°£ÁúÁ¦, ´ë»ç ±æÇ×Á¦, ±âŸ ¾àÁ¦ Ŭ·¡½º), Åõ¿© °æ·Îº°(°æ±¸ Åõ¿©, ±¹¼Ò Åõ¿©, ºñ°æ±¸ Åõ¿©, ±âŸ Åõ¿© °æ·Î), À¯Åë ä³Î(¼Ò¸Å ¾à±¹ À¯Åë ä³Î, º´¿ø ¾à±¹ À¯Åë ä³Î, ¿Â¶óÀÎ ¾à±¹ À¯Åë ä³Î), ¿ëµµ(Á¾¾çÇÐ ¿ëµµ, ¼øÈ¯±â ¿µ¿ª ¿ëµµ, ½Å°æ ¿µ¿ª ¿ëµµ, ¼ÒÈ­±â ¿µ¿ª ¿ëµµ, ÇǺΠ¿µ¿ª ¿ëµµ, ±Þ¼º/¸¸¼º ÅëÁõ ¿µ¿ª ¿ëµµ, ±âŸ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ¼­, ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Branded Generics Market to Reach US$328.5 Billion by 2030

The global market for Branded Generics estimated at US$256.3 Billion in the year 2024, is expected to reach US$328.5 Billion by 2030, growing at a CAGR of 4.2% over the analysis period 2024-2030. Anti-Hypertensive Drugs, one of the segments analyzed in the report, is expected to record a 4.2% CAGR and reach US$67.5 Billion by the end of the analysis period. Growth in the Alkylating Agents segment is estimated at 3.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$69.8 Billion While China is Forecast to Grow at 7.7% CAGR

The Branded Generics market in the U.S. is estimated at US$69.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$67.0 Billion by the year 2030 trailing a CAGR of 7.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.8% and 3.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.5% CAGR.

Global Branded Generics Market - Key Trends & Drivers Summarized

Why Are Branded Generics Gaining Market Traction?

Branded generics are becoming increasingly popular as they offer a cost-effective alternative to branded prescription drugs while maintaining quality and efficacy. These drugs are repackaged and marketed under a brand name, often by the original manufacturer or another pharmaceutical company. With the rising costs of branded medications and the growing need for affordable healthcare, branded generics are filling a crucial gap in the pharmaceutical market. Healthcare providers and patients alike are opting for branded generics due to their reliability, regulatory approvals, and cost benefits. As governments worldwide push for generic drug adoption to lower healthcare expenses, branded generics are expected to witness a steady rise in demand.

How Are Regulations and Market Strategies Shaping the Industry?

The regulatory landscape plays a vital role in the growth of the branded generics market. Many countries have streamlined their drug approval processes to encourage generic drug adoption, making it easier for pharmaceutical companies to introduce branded generics. Patent expirations of blockbuster drugs have also opened opportunities for drugmakers to rebrand generic equivalents, providing an additional revenue stream. Additionally, strategic marketing initiatives, such as physician endorsements, aggressive pricing strategies, and consumer awareness campaigns, are helping pharmaceutical firms expand their branded generics portfolios. With increasing market competition, companies are investing in innovative formulations and biosimilars to differentiate their offerings and gain a competitive edge.

Which Therapeutic Areas Are Driving Branded Generics Adoption?

Branded generics are making significant inroads across multiple therapeutic segments, including cardiovascular diseases, oncology, neurology, and diabetes management. The demand for cost-effective chronic disease treatments is one of the primary drivers of market expansion. In emerging economies, where healthcare infrastructure is still developing, branded generics provide an affordable alternative for long-term disease management. Additionally, biosimilars, a fast-growing segment within branded generics, are revolutionizing treatments for autoimmune disorders and cancer, reducing dependency on expensive biologics. The increasing burden of lifestyle diseases and the need for accessible treatment options are fueling the adoption of branded generics across diverse medical fields.

What Factors Are Driving Market Growth?

The growth in the branded generics market is driven by several factors, including rising healthcare costs, increasing patent expirations, and the expansion of pharmaceutical distribution networks. Governments and insurance companies are actively promoting the use of branded generics to control medication costs and enhance drug accessibility. Additionally, pharmaceutical companies are leveraging digital platforms and e-commerce channels to enhance product availability and consumer outreach. The rise of personalized medicine and targeted therapies is also influencing the development of advanced branded generics with improved efficacy and safety profiles. As the pharmaceutical industry continues to evolve, branded generics are expected to play an integral role in balancing cost efficiency with quality healthcare solutions.

SCOPE OF STUDY:

The report analyzes the Branded Generics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Anti-Hypertensive Drugs, Alkylating Agents, Hormones, Lipid Lowering Drugs, Anti-Depressants, Anti-Psychotics, Anti-Epileptics, Antimetabolites, Other Drug Classes); Administration Route (Oral Administration, Topical Administration, Parenteral Administration, Other Administration Routes); Distribution Channel (Retail Pharmacy Distribution Channel, Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel); Application (Oncology Application, Cardiovascular Diseases Application, Neurological Diseases Application, Gastrointestinal Diseases Application, Dermatological Diseases Application, Acute and Chronic Pain Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â